{"meshTags":["Carrier Proteins","Proto-Oncogene Proteins","Carcinoma, Non-Small-Cell Lung","Protein-Tyrosine Kinases","Membrane Proteins","Oncogene Proteins, Fusion","Animals","Lung Neoplasms","Humans"],"meshMinor":["Carrier Proteins","Proto-Oncogene Proteins","Carcinoma, Non-Small-Cell Lung","Protein-Tyrosine Kinases","Membrane Proteins","Oncogene Proteins, Fusion","Animals","Lung Neoplasms","Humans"],"genes":["ROS1","ROS1 fusions","ROS1","ROS1"],"publicationTypes":["Comment","Journal Article"],"abstract":"Rimkunas and colleagues report on the development and validation of an immunohistochemical assay evaluating non-small cell lung cancers (NSCLC) for the presence of ROS1 fusions. The diagnostic was validated in a screen of 556 NSCLCs, identifying 9 (1.6%) tumors with oncogenic ROS1 rearrangements. These patients are candidates for ROS1-targeted therapies.","title":"Zeroing in on ROS1 rearrangements in non-small cell lung cancer.","pubmedId":"22859716"}